Conversion to generic cyclosporine A in stable chronic patients after heart transplantation

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 1421-1426

  Kraeuter, Maximilian ^a   Helmschrott, Matthias ^a   Erbel, Christian ^a   Gleissner, Christian A ^a   Frankenstein, Lutz ^a   Schmack, Bastian ^a   Ruhparwar, Arjang ^a   Ehlermann, Philipp ^a   Katus, Hugo A ^a   Doesch, Andreas O ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Generic cyclosporine A; Heart transplantation; Immunosuppression

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; EVEROLIMUS; GENERIC DRUG; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ADULT; AGED; ARTICLE; CHRONIC PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG METABOLISM; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; LEUKOCYTE; MALE; OPERATION DURATION; PATIENT COMPLIANCE; PATIENT PREFERENCE; RETROSPECTIVE STUDY; SIDE EFFECT; STABLE CHRONIC PATIENT; THROMBOCYTE; TREATMENT DURATION;

GENERIC CYCLOSPORINE A; HEART TRANSPLANTATION; IMMUNOSUPPRESSION;

AGED; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SUBSTITUTION; DRUGS, GENERIC; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84888394524     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S54245     Document Type: Article

References (11)

1. Borel JF. History of the discovery of cyclosporin and of its early pharmacological development. Wien Klin Wochenschr. 2002;114(12): 433-437.
2. Pollard S, Nashan B, Johnston A, et al; CONSENT: Consensus on Substitution in European Transplantation. A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Berlin, Germany, November 19, 2001. Clin Ther. 2003;25(6):1654-1669.
3. Vítko S, Ferkl M. Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of Equoral and Neoral capsules in an international, multicenter, randomized, open-label trial. Kidney Int Suppl. 2010;(115):S12-S16.
4. Niemczyk M, Paczek L. Generic formulation of Cyclosporine A, Equoral®, in de novo kidney transplant recipients: five-year follow-up. Ann Transplant. 2011;16(2):59-62.
5. Billingham M, Kobashigawa JA. The revised ISHLT heart biopsy grading scale. J Heart Lung Transplant. 2005;24(11):1709.
6. Karapirli M, Kizilgun M, Yesilyurt O, et al. Simultaneous determination of cyclosporine A, tacrolimus, sirolimus, and everolimus in whole-blood samples by LC-MS/MS. Scientific World Journal. 2012;2012:571201.
7. Perlik F, Masri MA, Rost M, Kamarád V. Pharmacokinetic conversion study of a new cyclosporine formulation in stable adult renal transplant recipients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2005;149(2):309-313.
8. Maziers N, Bulpa P, Jamart J, Delaunois L, Eucher P, Evrard P. Correlations between cyclosporine concentrations at 2 hours post-dose and trough levels with functional outcomes in de novo lung transplant recipients. Transplant Proc. 2012;44(9):2880-2884.
9. Helderman JH, Kang N, Legorreta A P, Chen J Y. Healthcare costs in renal transplant recipients using branded versus generic ciclosporin. Appl Health Econ Health Policy. 2010;8(1):61-68.
10. Knight SR, Morris PJ. The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation. 2007;83(12): 1525-1535.
11. Harrison JJ, Schiff JR, Coursol CJ, et al. Generic immunosuppression in solid organ transplantation: a Canadian perspective. Transplantation. 2012;93(7):657-665.